The9 Says Investee Nanyang Biologics Received SEC Notice Of Effectiveness For Form F-4 Ahead Of Nasdaq Listing At $1.5B Pre-Transaction Valuation; Expects To Own 15% To 16% Of Combined Company
Share
Why It Matters
A company that The9 invested in (Nanyang Biologics) got approval to list on Nasdaq, a big stock market, at a $1.5 billion value. The9 will own about 15–16% of the combined business after the listing happens.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.